Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Tatsuhiko Ozawa; Hideki Tani; Yuki Anraku; Shunsuke Kita; Emiko Igarashi; Yumiko Saga; Noriko Inasaki; Hitoshi Kawasuji; Hiroshi Yamada; So-Ichiro Sasaki; Mayu Somekawa; Jiei Sasaki; Yoshihiro Hayakawa; Yoshihiro Yamamoto; Yoshitomo Morinaga; Nobuyuki Kurosawa; Masaharu Isobe; Hideo Fukuhara; Katsumi Maenaka; Takao Hashiguchi; Hiroyuki Kishi; Isao Kitajima; Shigeru Saito; Hideki Niimi

doi:10.1080/19420862.2022.2072455

Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Tatsuhiko Ozawa^*, Hideki Tani, Yuki Anraku, Shunsuke Kita, Emiko Igarashi, Yumiko Saga, Noriko Inasaki, Hitoshi Kawasuji, Hiroshi Yamada, So-Ichiro Sasaki, Mayu Somekawa, Jiei Sasaki, Yoshihiro Hayakawa, Yoshihiro Yamamoto, Yoshitomo Morinaga, Nobuyuki Kurosawa, Masaharu Isobe, Hideo Fukuhara, Katsumi Maenaka, Takao HashiguchiHiroyuki Kishi, Isao Kitajima, Shigeru Saito, Hideki Niimi^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

Original language	English
Pages (from-to)	2072455
Journal	mAbs
Volume	14
Issue number	1
DOIs	https://doi.org/10.1080/19420862.2022.2072455
State	Published - 2022/05/12

Keywords

Antibodies, Neutralizing
Antibodies, Viral
COVID-19/prevention & control
Humans
SARS-CoV-2

Access to Document

10.1080/19420862.2022.2072455

Cite this

Ozawa, T., Tani, H., Anraku, Y., Kita, S., Igarashi, E., Saga, Y., Inasaki, N., Kawasuji, H., Yamada, H., Sasaki, S.-I., Somekawa, M., Sasaki, J., Hayakawa, Y., Yamamoto, Y., Morinaga, Y., Kurosawa, N., Isobe, M., Fukuhara, H., Maenaka, K., ... Niimi, H. (2022). Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. mAbs, 14(1), 2072455. https://doi.org/10.1080/19420862.2022.2072455

@article{8578d978bfd644c6993eb9b94cb1e4fc,

title = "Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants",

abstract = "Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.",

keywords = "Antibodies, Neutralizing, Antibodies, Viral, COVID-19/prevention & control, Humans, SARS-CoV-2",

author = "Tatsuhiko Ozawa and Hideki Tani and Yuki Anraku and Shunsuke Kita and Emiko Igarashi and Yumiko Saga and Noriko Inasaki and Hitoshi Kawasuji and Hiroshi Yamada and So-Ichiro Sasaki and Mayu Somekawa and Jiei Sasaki and Yoshihiro Hayakawa and Yoshihiro Yamamoto and Yoshitomo Morinaga and Nobuyuki Kurosawa and Masaharu Isobe and Hideo Fukuhara and Katsumi Maenaka and Takao Hashiguchi and Hiroyuki Kishi and Isao Kitajima and Shigeru Saito and Hideki Niimi",

year = "2022",

month = may,

day = "12",

doi = "10.1080/19420862.2022.2072455",

language = "英語",

volume = "14",

pages = "2072455",

journal = "mAbs",

issn = "1942-0862",

publisher = "Landes Bioscience",

number = "1",

}

Ozawa, T, Tani, H, Anraku, Y, Kita, S, Igarashi, E, Saga, Y, Inasaki, N, Kawasuji, H , Yamada, H, Sasaki, S-I, Somekawa, M, Sasaki, J, Hayakawa, Y , Yamamoto, Y , Morinaga, Y , Kurosawa, N , Isobe, M, Fukuhara, H, Maenaka, K, Hashiguchi, T, Kishi, H , Kitajima, I , Saito, S & Niimi, H 2022, 'Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants', mAbs, vol. 14, no. 1, pp. 2072455. https://doi.org/10.1080/19420862.2022.2072455

TY - JOUR

T1 - Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

AU - Ozawa, Tatsuhiko

AU - Tani, Hideki

AU - Anraku, Yuki

AU - Kita, Shunsuke

AU - Igarashi, Emiko

AU - Saga, Yumiko

AU - Inasaki, Noriko

AU - Kawasuji, Hitoshi

AU - Yamada, Hiroshi

AU - Sasaki, So-Ichiro

AU - Somekawa, Mayu

AU - Sasaki, Jiei

AU - Hayakawa, Yoshihiro

AU - Yamamoto, Yoshihiro

AU - Morinaga, Yoshitomo

AU - Kurosawa, Nobuyuki

AU - Isobe, Masaharu

AU - Fukuhara, Hideo

AU - Maenaka, Katsumi

AU - Hashiguchi, Takao

AU - Kishi, Hiroyuki

AU - Kitajima, Isao

AU - Saito, Shigeru

AU - Niimi, Hideki

PY - 2022/5/12

Y1 - 2022/5/12

N2 - Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

AB - Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

KW - Antibodies, Neutralizing

KW - Antibodies, Viral

KW - COVID-19/prevention & control

KW - Humans

KW - SARS-CoV-2

U2 - 10.1080/19420862.2022.2072455

DO - 10.1080/19420862.2022.2072455

M3 - 学術論文

C2 - 35543180

SN - 1942-0862

VL - 14

SP - 2072455

JO - mAbs

JF - mAbs

IS - 1

ER -

Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Abstract

Keywords

Access to Document

Fingerprint

Cite this